Amanda Laviolette, MD
Internal Medicine · Austin, TXNPI 1538363106
Payments from drug & device makers
Across 207 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$516
- Abbott$430
- Lilly USA, LLC$326
- Boehringer Ingelheim$192
- Amgen$134
- plus $893 from 19 others
What the payments were for
- Food & beverage$3,45299%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $1,008 |
| Novo Nordisk | 29 | $516 |
| Abbott | 28 | $430 |
| Lilly USA, LLC | 27 | $326 |
| Boehringer Ingelheim | 10 | $192 |
| Amgen | 9 | $134 |
| AbbVie | 7 | $114 |
| Astellas Pharma US Inc | 8 | $108 |
| Kerecis Limited | 1 | $98 |
| Pfizer | 5 | $88 |
| Johnson & Johnson | 6 | $87 |
| Atricure, Inc. | 1 | $45 |
| Gilead | 3 | $44 |
| Novartis | 3 | $42 |
| Merck | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Sanofi Pasteur Inc. | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Alvogen Inc | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Bayer | 1 | $18 |
| Metuchen Pharmaceuticals | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Exact Sciences | 1 | $13 |
How this compares
$3,499 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $71,044 |
| JardianceEmpagliflozin | 46 | $63,795 |
| XareltoRivaroxaban | 59 | $60,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $52,543 |
| Repatha SureclickEvolocumab | 59 | $47,053 |
| MyrbetriqMirabegron | 56 | $37,666 |
| RybelsusSemaglutide | 31 | $37,187 |
| EliquisApixaban | 37 | $35,763 |
| Mirabegron ErMirabegron | 51 | $29,275 |
| JanuviaSitagliptin Phosphate | 18 | $25,861 |
| TrulicityDulaglutide | 12 | $17,539 |
| Praluent PenAlirocumab | 22 | $12,242 |
| Estradiol | 118 | $10,766 |
| BelsomraSuvorexant | 16 | $9,061 |
| GemtesaVibegron | 14 | $9,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $516 | $108,23185 claims |
| Boehringer IngelheimJardiance | $192 | $63,79546 claims |
| Johnson & JohnsonXarelto | $87 | $60,32759 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,008 | $58,46969 claims |
| PfizerEliquis, Prempro | $88 | $39,94449 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $37,66656 claims |
| MerckJanuvia, Belsomra | $36 | $34,92234 claims |
| Lilly USA, LLCTrulicity | $326 | $17,53912 claims |
| AbbVieSynthroid | $114 | $4,951113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Austin
- Theresa PhamAustin$6.3M
- Lu Ann BundrantAustin$5.4M
- Antonia DavidsonAustin$4.2M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.